IL91649A - A polydoma that produces, produces and uses two specific hybrid monoclonal antibodies against fibrin and pro-urokines - Google Patents
A polydoma that produces, produces and uses two specific hybrid monoclonal antibodies against fibrin and pro-urokinesInfo
- Publication number
- IL91649A IL91649A IL9164989A IL9164989A IL91649A IL 91649 A IL91649 A IL 91649A IL 9164989 A IL9164989 A IL 9164989A IL 9164989 A IL9164989 A IL 9164989A IL 91649 A IL91649 A IL 91649A
- Authority
- IL
- Israel
- Prior art keywords
- antibody
- fibrin
- tpa
- prourokinase
- hybridoma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24354488 | 1988-09-27 | ||
| JP30192588 | 1988-11-28 | ||
| JP6294089 | 1989-03-14 | ||
| JP16487389 | 1989-06-27 | ||
| JP20893689A JP3177776B2 (ja) | 1988-09-27 | 1989-08-11 | ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL91649A0 IL91649A0 (en) | 1990-04-29 |
| IL91649A true IL91649A (en) | 1994-10-21 |
Family
ID=27523741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9164989A IL91649A (en) | 1988-09-27 | 1989-09-15 | A polydoma that produces, produces and uses two specific hybrid monoclonal antibodies against fibrin and pro-urokines |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5506135A (fi) |
| EP (1) | EP0363712B1 (fi) |
| JP (1) | JP3177776B2 (fi) |
| KR (1) | KR900004351A (fi) |
| CN (1) | CN1041783A (fi) |
| AR (1) | AR242832A1 (fi) |
| AT (1) | ATE140930T1 (fi) |
| AU (1) | AU628857B2 (fi) |
| DE (1) | DE68926899T2 (fi) |
| DK (1) | DK474189A (fi) |
| FI (1) | FI894551A (fi) |
| HU (1) | HUT55445A (fi) |
| IL (1) | IL91649A (fi) |
| NO (1) | NO893818L (fi) |
| PT (1) | PT91808B (fi) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030068322A1 (en) * | 1988-04-18 | 2003-04-10 | Immunomedics, Inc. | Methods of antibody-directed enzyme-prodrug therapy |
| TW212184B (fi) * | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
| JPH0576385A (ja) * | 1990-12-18 | 1993-03-30 | Takeda Chem Ind Ltd | キメラ抗体およびその用途 |
| WO1992019973A1 (en) * | 1991-04-26 | 1992-11-12 | Surface Active Limited | Novel antibodies, and methods for their use |
| WO2015053381A1 (ja) * | 2013-10-10 | 2015-04-16 | 幸成 加藤 | 抗ポドプラニン抗体 |
| EP3620471A4 (en) * | 2017-05-02 | 2021-01-06 | National Cancer Center Japan | ANTIBODY-ANTI-FIBRIN DRUG CONJUGATE INSOLUBLE, POSSIBLE TO BE CLIVID BY PLASMINE |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4714681A (en) * | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| CA1213229A (en) * | 1982-04-12 | 1986-10-28 | Gary S. David | Antibodies having dual specificities, their preparation and uses therefor |
| US4916070A (en) * | 1986-04-14 | 1990-04-10 | The General Hospital Corporation | Fibrin-specific antibodies and method of screening for the antibodies |
| JP2635343B2 (ja) * | 1986-04-14 | 1997-07-30 | ザ・ジェネラル・ホスピタル・コーポレーション | ヘテロ二官能性抗体および利用方法 |
-
1989
- 1989-08-11 JP JP20893689A patent/JP3177776B2/ja not_active Expired - Fee Related
- 1989-09-15 IL IL9164989A patent/IL91649A/en not_active IP Right Cessation
- 1989-09-23 DE DE68926899T patent/DE68926899T2/de not_active Expired - Fee Related
- 1989-09-23 EP EP89117622A patent/EP0363712B1/en not_active Expired - Lifetime
- 1989-09-23 AT AT89117622T patent/ATE140930T1/de not_active IP Right Cessation
- 1989-09-25 AR AR89314993A patent/AR242832A1/es active
- 1989-09-25 AU AU41747/89A patent/AU628857B2/en not_active Ceased
- 1989-09-26 PT PT91808A patent/PT91808B/pt not_active IP Right Cessation
- 1989-09-26 NO NO89893818A patent/NO893818L/no unknown
- 1989-09-26 DK DK474189A patent/DK474189A/da not_active Application Discontinuation
- 1989-09-26 FI FI894551A patent/FI894551A/fi not_active IP Right Cessation
- 1989-09-27 HU HU895091A patent/HUT55445A/hu unknown
- 1989-09-27 CN CN89107488A patent/CN1041783A/zh active Pending
- 1989-09-27 KR KR1019890013907A patent/KR900004351A/ko not_active IP Right Cessation
-
1994
- 1994-12-29 US US08/366,366 patent/US5506135A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1041783A (zh) | 1990-05-02 |
| JP3177776B2 (ja) | 2001-06-18 |
| US5506135A (en) | 1996-04-09 |
| DK474189A (da) | 1990-03-28 |
| DE68926899T2 (de) | 1997-01-02 |
| AR242832A1 (es) | 1993-05-31 |
| PT91808A (pt) | 1990-03-30 |
| EP0363712B1 (en) | 1996-07-31 |
| KR900004351A (ko) | 1990-04-12 |
| PT91808B (pt) | 1995-05-31 |
| FI894551A (fi) | 1990-03-28 |
| NO893818L (no) | 1990-03-28 |
| FI894551A0 (fi) | 1989-09-26 |
| ATE140930T1 (de) | 1996-08-15 |
| DK474189D0 (da) | 1989-09-26 |
| EP0363712A3 (en) | 1990-08-16 |
| AU4174789A (en) | 1990-04-05 |
| EP0363712A2 (en) | 1990-04-18 |
| IL91649A0 (en) | 1990-04-29 |
| AU628857B2 (en) | 1992-09-24 |
| NO893818D0 (no) | 1989-09-26 |
| HUT55445A (en) | 1991-05-28 |
| JPH03103175A (ja) | 1991-04-30 |
| DE68926899D1 (de) | 1996-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0450479B1 (en) | Bispecific monoclonal anti-bodies, their production and use | |
| EP0419574B1 (en) | Monoclonal antibodies to the light chain region of human factor xii and methods of preparing and using the same | |
| KR100585473B1 (ko) | 혈액 응고를 억제하기 위한 항체 및 그의 사용 방법 | |
| US20090252726A1 (en) | Antibodies for inhibiting blood coagulation and methods of use thereof | |
| KR20050040844A (ko) | 혈액 응고를 억제하기 위한 항체 및 이의 사용 방법 | |
| JPH05304992A (ja) | ハイブリッド・モノクローナル抗体および抗体含有薬剤 | |
| EP0241907A2 (en) | Heterobifunctional antibodies and method of use | |
| EP0363712B1 (en) | Hybrid monoclonal antibodies, their production and use | |
| EP0139447B1 (en) | A process for preparing urokinase zymogen | |
| US5620688A (en) | Methods of inhibiting the activation of Factor XIII | |
| US5453269A (en) | Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use | |
| Kurokawa et al. | Enhanced fibrinolysis by a bispecific monoclonal antibody reactive to fibrin and tissue plasminogen activator | |
| Hayzer et al. | Conjugation of plasminogen activators and fibrin-specific antibodies to improve thrombolytic therapeutic agents | |
| US7247453B1 (en) | Calcium binding recombinant antibody against protein C | |
| EP0513778A2 (en) | Hybrid monoclonal antibodies and compositions containing them | |
| EP0491351A2 (en) | Chimeric antibodies and their use | |
| JPH02142494A (ja) | 抗ウロキナーゼモノクローナル抗体 | |
| JPS61186399A (ja) | 抗ヒトアンジオテンシン変換酵素抗体 | |
| JPH04218389A (ja) | 二重特異性抗体および抗体含有薬剤 | |
| Charpie | Monoclonal antibodies specific for single-chain urokinase: applications in targeted thrombolysis | |
| CA2056118A1 (en) | Monoclonal antibodies which bind mannose binding protein | |
| JPH0575394B2 (fi) | ||
| JPH0995500A (ja) | モノクローナル抗体および血栓溶解促進剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RH | Patent void |